Although this is limited to one patient, results are in-line with a recent study suggesting that EGFR-mutated NSCLC patients with KRAS mutations detected in tumor before the start of treatment do not benefit from EGFR TKIs (22). This evidence concerns the gene KRAS and non-small cell lung carcinoma.